论文部分内容阅读
目的研究多药耐药(MDR1)基因C3435T多态性与晚期胃癌患者对5-氟尿嘧啶(5-FU)/奥沙利铂(OXA)为基础的方案化疗敏感性的关系。方法病理学确诊晚期胃癌患者82例,化疗前采集外周静脉血,提取DNA,采用RT-PCR技术检测MDR1C3435T基因型。分析基因型与化疗疗效的关系。结果 82例晚期胃癌患者中,35例(42.68%)为MDR1C3435TC/C基因型,34例(41.46%)为C/T基因型,13例(15.85%)为T/T基因型。其中,2例完全缓解(CR),30例部分缓解(PR),25例稳定(SD),25例进展(PD);总有效率为39.02%(32/82)。C/C基因型患者的化疗有效率57.14%,高于C/T基因型的26.47%和T/T基因型的23.08%(P<0.05)。结论 MDR1基因C3435T多态性与晚期胃癌患者对5-FU/OXA为基础方案的化疗敏感性相关。
Objective To investigate the relationship between multidrug resistance (MDR1) gene C3435T polymorphism and 5-fluorouracil (5-FU) / oxaliplatin (OXA) -based chemotherapy in patients with advanced gastric cancer. Methods Eighty-two patients with advanced gastric cancer were diagnosed by pathology. Peripheral venous blood was collected before chemotherapy and DNA was extracted. The genotypes of MDR1C3435T were detected by RT-PCR. Analysis of the relationship between genotype and chemotherapy efficacy. Results Among 82 patients with advanced gastric cancer, 35 (42.68%) were MDR1C3435TC / C genotypes, 34 (41.46%) were C / T genotypes and 13 (15.85%) were T / T genotypes. Among them, 2 cases were complete remission (CR), 30 partial remission (PR), 25 stable (SD) and 25 cases progressive (PD). The total effective rate was 39.02% (32/82). The chemotherapy efficiency of C / C genotype was 57.14%, higher than that of C / T genotype 26.47% and T / T genotype 23.08% (P <0.05). Conclusion The C3435T polymorphism of MDR1 gene is associated with chemosensitivity to 5-FU / OXA-based regimen in patients with advanced gastric cancer.